CD200R1 and cancer: Nevertheless, there is a debate regarding the beneficial effects that the blockage of CD200-CD200R axis may have in cancer patients (141), since following treatment with chemotherapeutic agents such as doxorubicin, the recruitment of functional DCs in the TME claims the CD200-CD200R pathway (165).